Think about factors like how easily you can remember to take your doses, how your schedule looks, and your comfort level with injections
Moving from insulin to GLP-1 A patient on basal insulin whose Type 2 diabetes is relatively well controlled might transition to a GLP-1 agonist if they are gaining excessive weight on insulin, want to simplify their regimen, have developed cardiovascular risk factors that would benefit from GLP-1 protection, or have adequate remaining beta cell function
Clinical Evidence: Behavioral Weight Loss vs
The key difference is the magnitude of the result
Michael White, professor of pharmacy practice at the University of Connecticut School of Pharmacy, is skeptical, to say the least: The marketing seems to suggest that you could get with these natural products, these natural ingredients, the same effect that you can get with GLP-1 agonists, which is simply not the case